(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
about
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusTarget Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular ImagingUpdates of prostate cancer staging: Prostate-specific membrane antigenSingle fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyProstate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI.Prostate Cancer Imaging with Novel PET Tracers.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review.Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.PSMA PET and Radionuclide Therapy in Prostate Cancer.The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.Metal-Based PSMA Radioligands.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CTMultisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate CancerCurrent status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.Current status of theranostics in prostate cancer.68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
P2860
Q26774920-403863EF-EA34-444E-9E03-0BC3CF0B7AF7Q28074669-5A5F5608-FEEE-4D79-84C0-4DF14F1CB454Q28079444-06777BFF-4E86-49EB-8AE4-EF8FAB25912BQ30376901-C83FC09B-DE95-479F-B404-568F4DD47B07Q33841484-07092D9F-5CE3-4EF0-AD8B-BF5F4D9AB6C4Q33914844-1932422E-B3B2-4345-9743-6892C7ED60E9Q36289592-74ED9BEC-CD9D-4602-8DE0-1D6FBF326616Q37273884-1653A765-3DBC-41EB-9AB5-E4FD7300F77EQ37554235-CB010A85-0550-42EA-8586-04FCFF9662C0Q37626953-1795847C-C9CC-46B3-AF07-1808D0EF88D3Q38732369-F8E6AA66-51F1-4736-8076-EA43821FC882Q38747415-A58A6F60-9012-476D-B8CD-452F475134EBQ38757513-8F8E844E-ED43-472E-9AC1-E69828B4A427Q38762963-77DD68BA-1DF3-4B8A-AB80-C4501E5B98F1Q38804450-23EFC5E5-0745-435E-8FF6-93765A153382Q38831232-5A12AC20-165B-4281-B356-8F5D80E39BA4Q38952552-2FE6F411-0F99-4BEA-9A23-532C029F53CFQ38966705-BBAB656A-7656-4AEB-AC08-ED4C16C085E9Q39003089-F108F82F-F9F2-48CD-B48C-CB695ED80C87Q39143896-30397458-B6BB-47A5-AEB0-B37C910F3D22Q39198527-2B371383-8D9E-48C9-BE71-C4635B914D51Q39242140-09DD8AF2-FCFE-42A3-A92B-D7A4DBAC1008Q39276928-6F34E988-DE69-49A0-BA36-E7451C9C6535Q39572115-B87163E5-EECD-431D-ABC2-C2AA8C34B8C1Q39699773-97FB5053-CF8E-4201-B581-91C9406EBE6AQ39922053-E8233C88-05D6-4479-92FF-A8336F5909DCQ42379563-65A60544-4C45-4610-AD8B-9A30E2A03FBBQ43846086-FA1620BF-31DC-447B-85EA-08D3E7739E63Q46225464-6A555D85-252A-43B7-9761-F9D1EBF8FD5AQ47107456-8A6D414D-B7A0-4E4F-9995-07F33253FD72Q47241139-996E7ED7-8AD7-4D8E-9618-1E29B143BA08Q47273452-0087329B-AAF8-40D5-8472-B4A3F8C52A19Q47438555-C4285648-B5E4-4B85-AD53-4E157EEF2672Q47693515-44537D8D-8BF2-4663-9607-E32D4BDD2358Q47805128-A3D73F64-CC5F-44E2-B924-06E315F472B0Q48089415-3774284D-BB49-4B19-9056-F77A3E11EEACQ48139886-23C0D407-7C50-4AD6-A2E9-61331F9D9354Q48177983-335AD0F2-C18B-40A5-B229-990D67194182Q48189196-3564EB56-028C-4324-B7FB-841BD0015D4DQ48226517-1F099475-6DBB-4239-B2C9-CB310294542D
P2860
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?
@en
type
label
(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?
@en
prefLabel
(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?
@en
P2093
P2860
P50
P1476
(68)Ga-PSMA PET/CT for restagi ...... ed with PET/CT detection rate?
@en
P2093
Alexander Kroiss
Bernhard Nilica
Christian Uprimny
Dorota Kendler
Irene J Virgolini
Jasmin Bektic
Llanos Geraldo
Paolo Castellucci
Peter Lukas
Wolfgang Horninger
P2860
P2888
P304
P356
10.1007/S00259-015-3078-6
P577
2015-05-15T00:00:00Z